UPM Pharmaceuticals, a Contract Development and Manufacturing Organization (CDMO) focused on solid oral and semi-solid dosage forms, has appointed Chris Curtin as Chief Operating Officer. Mr. Curtin was promoted from his previous role as Executive Vice President of Quality Operations. Mr. Curtin will lead the organization responsible for Research & Development, Manufacturing, Quality Assurance, Inventory Management, Quality Control and Analytical Services.
Originally published on 9/01/2018 at Drug Development & Delivery
UPM Pharmaceuticals successfully serialized their first product in May of this year. UPM anticipates having all of their clients' products serialized by November 2017. In accordance with the Drug Supply Chain Security Act which had mandated that pharmaceutical manufacturers serialize all pharmaceutical products starting in November 2017, UPM is excited to be ahead of schedule. All products will be serialized by the FDA’s extended deadline of November 2018, if not before.
Originally published on 6/21/2017 at Pharma's Almanac
Read our latest article, as published in the Q2 2017 edition of Pharma's Almanac.
Interview originally published on 20/04/2017 at Pharma's Almanac
Interview originally published on 06/04/2017 at Pharma's Almanac
Read our latest article, as published in the Q1 2017 edition of Pharma's Almanac.
Read our latest article, as published in the Q4 2016 edition of Pharma's Almanac.
UPM is excited to announce the opening of its newly designed and qualified Solids Formulation R&D Facility.
